Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 3


Recommendation based on results from the Phase 3 CheckMate -816 trial, in which Opdivo with chemotherapy demonstrated improved event-free survival and pathologic complete response compared to chemotherapy alone when administered before surgery If approved, Opdivo with chemotherapy would be the first and only neoadjuvant immunotherapy-based option authorized to treat patients with non-small cell...

  • 123456 Profile photo of Madelyn

    We see so many patients with resectable lung cancer. CHECKMATE 816 led to the approval of neoadjuvant nivolumab + chemo due to increased pathologic CR rates. The product is only approved for PD-L1 over 1% in Europe unlike all comers by the FDA. Should we really give it to all? Trial design has limitations, financial toxicity is real, and patient toxicity is real.